Diabetic Neuropathy

In humans, one of the leading causes of neuropathic pain is diabetic neuropathy (DN). In Western countries, the prevalence of DN is about 20% in patients with type 2 diabetes and 5% in those with type 1, although the diagnosis is compromised by the incidence of DN that presents without pain. DN treatment consists first of all in improving glycemic control and lifestyle intervention. Pain control with the available drugs (tricyclic antidepressants, anticonvulsants, selective serotonin-reuptake inhibitors) shows that efficacy and tolerability are not ideal.

Several diabetic models are available such as insulin deficient or insulin resistant models. But the most commonly used model for the study of pain is the Streptozotocin-induced diabetic NP model (STZ model).This model has been used extensively for testing of new compounds as in the case of gabapentin and pregabalin.

 

buttom TA